Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18919036 | 1.00 | CNR2 (0.43) | CNR2GPR183HTR2AMAPTACHE | |
| SCHEMBL18932680 | 0.92 | GPR183 (0.41) | CNR2GPR183HTR2AMAPTACHE | |
| SCHEMBL18919182 | 0.91 | GPR183 (0.42) | CNR2GPR183HTR2ADNM1OPRM1 | |
| SCHEMBL18919180 | 0.91 | GPR183 (0.42) | CNR2GPR183HTR2ADNM1OPRM1 | |
| SCHEMBL18919215 | 0.91 | DNM1 (0.43) | CNR2GPR183MAPTDNM1 | |
| SCHEMBL18919214 | 0.91 | DNM1 (0.43) | CNR2GPR183MAPTDNM1 | |
| SCHEMBL18919050 | 0.90 | CNR2 (0.44) | CNR2GPR183HTR2AMAPTACHE | |
| SCHEMBL18919051 | 0.90 | CNR2 (0.44) | CNR2GPR183HTR2AMAPTACHE | |
| SCHEMBL18919204 | 0.90 | KMT2A (0.43) | GPR183ACHESIGMAR1 | |
| SCHEMBL18919202 | 0.90 | KMT2A (0.43) | GPR183ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | CNR2 2724/4885GPR183 2755/4885HTR2A 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.